Urolithin A from Pomegranates Shows Promise in Improving Heart Function
A recent study from King's College London has revealed that urolithin A, a natural compound formed in the body after the consumption of foods such as pomegranates, walnuts, and certain berries, may enhance heart function by as much as 80% in experimental models of heart failure. This form of heart failure, known as heart failure with preserved ejection fraction (HFpEF), is particularly challenging to treat and affects nearly half a million individuals in the UK alone. In HFpEF, the heart retains its ability to pump blood but struggles to relax properly between beats, leading to difficulties in filling with blood. The condition is associated with symptoms such as shortness of breath, fatigue, and a reduced capacity for physical activity, ultimately impacting quality of life.
The study's senior author, Dr. Joseph Burgoyne, emphasized the growing prevalence of this type of heart failure, particularly as populations age and rates of obesity and diabetes rise. Despite its increasing burden, treatment options remain limited due to the complexity of the condition, which can be influenced by various factors, including aging, hypertension, and diabetes. Traditional heart failure treatments often prove ineffective because the heart can still pump normally but fails to relax adequately. Consequently, clinicians typically focus on managing underlying conditions and recommending lifestyle changes, such as weight loss and improved blood sugar control.
Urolithin A has garnered attention for its potential benefits related to healthy aging and mitochondrial function, which is crucial for energy production in the body. In this study, researchers discovered that urolithin A activates a protein known as PKGlα, which plays a vital role in blood vessel function and the relaxation of heart muscle. By targeting a specific amino acid within this protein, urolithin A triggers a beneficial pathway that enhances cardiovascular health.
In animal models, treatment with urolithin A resulted in significant improvements in heart function, with measures showing up to an 80% enhancement compared to untreated models. Laboratory experiments further demonstrated that urolithin A improved the relaxation of heart tissue and reduced fibrosis, which is the harmful scarring that can disrupt normal heart function. Additionally, the compound limited the enlargement of heart muscle cells, helping maintain their normal function.
The research team also explored the effects of urolithin A on engineered human heart tissue created from human stem cells, a sophisticated laboratory model that closely replicates the structure and function of human heart muscle. The findings indicated that urolithin A significantly improved relaxation in this engineered tissue, suggesting that the benefits observed in animal models may extend to human cardiac function.
Unlike many experimental compounds, urolithin A has already been studied in humans and has demonstrated a favorable safety profile. However, further research is necessary before these findings can lead to viable treatments for patients. The study highlights a promising therapeutic target and a naturally derived compound that could help address a significant unmet need in cardiovascular medicine.
Dr. Burgoyne noted, "This type of heart failure remains one of the most challenging forms of heart disease to treat. Our findings identify a completely new therapeutic target and show that urolithin A can activate this pathway to improve heart relaxation and reduce disease severity. This raises the exciting possibility of developing new treatments that improve clinical outcomes and quality of life for people living with the condition."
While the study does not provide sufficient evidence to recommend dietary changes for treating heart failure, it does suggest that enhancing urolithin A production through diet may offer potential benefits for alleviating this condition.
The study was funded by the British Heart Foundation and published in Science Advances, contributing to the ongoing exploration of innovative approaches to cardiovascular health.




